Scienture Holdings Valuation

Is SCNX undervalued compared to its fair value, analyst forecasts and its price relative to the market?

Valuation Score

2/6

Valuation Score 2/6

Below Fair Value
Significantly Below Fair Value
Price-To-Book vs Peers
Price-To-Book vs Industry
Price-To-Book vs Fair Ratio
Analyst Forecast

Share Price vs Fair Value

What is the Fair Price of SCNX when looking at its future cash flows? For this estimate we use a Discounted Cash Flow model.

Below Fair Value: Insufficient data to calculate SCNX's fair value for valuation analysis.

Significantly Below Fair Value: Insufficient data to calculate SCNX's fair value for valuation analysis.

Key Valuation Metric

Which metric is best to use when looking at relative valuation for SCNX?

Key metric: As SCNX is unprofitable and pre-revenue we use its Price-To-Book Ratio for relative valuation analysis.

The above table shows the Price to Book ratio for SCNX. This is calculated by dividing SCNX's market cap by their current book value.
What is SCNX's PB Ratio?
PB Ratio	0.8x
Book	US$85.13m
Market Cap	US$62.22m

SCNX key valuation metrics and ratios. From Price to Earnings, Price to Sales and Price to Book to Price to Earnings Growth Ratio, Enterprise Value and EBITDA.
Key Statistics
Enterprise Value/Revenue	-183.1x
Enterprise Value/EBITDA	n/a
PEG Ratio	n/a

Price to Book Ratio vs Peers

How does SCNX's PB Ratio compare to its peers?

The above table shows the PB ratio for SCNX vs its peers. Here we also display the market cap and forecasted growth for additional consideration.
Company	Forward PB	Estimated Growth	Market Cap
Peer Average	1001.1x
PTHL Pheton Holdings	4000.2x	n/a	US$63.1m
FORA Forian	2.4x	9.9%	US$63.9m
OPRX OptimizeRx	0.9x	51.7%	US$91.9m
CCLD CareCloud	1.1x	104.4%	US$50.3m
SCNX Scienture Holdings	0.8x	n/a	US$62.2m

Price-To-Book vs Peers: SCNX is good value based on its Price-To-Book Ratio (0.8x) compared to the peer average (1001.1x).

Price to Book Ratio vs Industry

How does SCNX's PB Ratio compare vs other companies in the US Healthcare Services Industry?

2 Companies	Price / Book	Estimated Growth	Market Cap
UPHL UpHealth	0.00009x	n/a	US$5.68k
PEAR.Q Pear Therapeutics	0.000005x	n/a	US$142.00

No more companies available in this PB range

2 Companies		Estimated Growth	Market Cap

No more companies

Price-To-Book vs Industry: SCNX is good value based on its Price-To-Book Ratio (0.8x) compared to the US Healthcare Services industry average (1.6x).

Price to Book Ratio vs Fair Ratio

What is SCNX's PB Ratio compared to its Fair PB Ratio? This is the expected PB Ratio taking into account the company's forecast earnings growth, profit margins and other risk factors.

SCNX PB Ratio vs Fair Ratio.
Fair Ratio
Current PB Ratio	0.8x
Fair PB Ratio	n/a

Price-To-Book vs Fair Ratio: Insufficient data to calculate SCNX's Price-To-Book Fair Ratio for valuation analysis.

Analyst Price Targets

What is the analyst 12-month forecast and do we have any statistical confidence in the consensus price target?

Analyst Forecast: Insufficient data to show price forecast.

Discover undervalued companies

Centene

US$30.3b

Operates as a healthcare enterprise that provides programs and services to under-insured and uninsured families, commercial organizations, and military families in the United States.

CNC

US$59.93

1.4%

-15.0%

Lantheus Holdings

US$6.2b

Develops, manufactures, and commercializes diagnostic and therapeutic products that assist clinicians in the diagnosis and treatment of heart, cancer, and other diseases worldwide.

LNTH

US$90.27

4.4%

28.9%

Sensus Healthcare

US$141.1m

A medical device company, manufactures and sells radiation therapy devices to healthcare providers worldwide.

SRTS

US$8.60

-3.8%

252.5%